Biobohemia is a biotechnology company engaged in research and development of innovative proprietary products in the field of oncology, and have discovered a potentially non-toxic, selective and targeted approach for treating various forms of cancer.
Biobohemia's lead product, SANTAVACTM
Set of All Natural Target Antigens for Vaccination Against Cancer) is an antigen composition developed by proteomics and cell culture technology and intended for development of cancer vaccines against solid tumors. The mechanism of action of SANTAVACTM
is based on the heterogeneity of endothelial cells, consisting of polypeptides similar to surface antigens of tumor-vessels cells allowing targeted destruction by vaccination. The SANTAVACTM
efficacy and mechanism of action is presented in series of peer-reviewed scientific papers